Celularity Inc. (NasdaqCM: CELU)
Health Care · Biotechnology · US
$0.98
-6.89% today · -50.9% 1Y
Celularity Inc. (NasdaqCM: CELU) operates in the Biotechnology industry within the Health Care sector. The company is valued at $31.73M and employs 115 people.
Over the last twelve months the share price has lost 50.9%, trading between 0.56 and 2.55.
Tweenvest scores Celularity Inc. across four factors: quality 18/100, value 55/100, growth 83/100. Its strongest factor is growth.
CELU price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $31.73M
- Revenue (TTM)
- $18.67M
- P/E
- —
- EPS
- -2.65
- Dividend yield
- —
- Beta (5Y)
- 0.78
- 52-week high
- $2.55
- 52-week low
- $0.56
- Avg volume (3M)
- —
- Shares outstanding
- 32.45M
- Employees
- 115
- Next earnings
- —
About Celularity Inc.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
- ISIN
- US1511902041
- Founded
- 1998
- Listed since
- Aug 8, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| QuantaMatrix Inc.KOSDAQ: A317690 | $32.77M | ₩2,170.00 | -6.26% |
| Kringle Pharma, Inc.TSE: 4884 | $32.60M | ¥614.00 | -4.81% |
| Quince Therapeutics, Inc.NasdaqGS: QNCX | $32.58M | $32.03 | +0.95% |
| GeneBioTech Co. ,LtdKOSDAQ: A086060 | $32.23M | ₩4,990.00 | -1.58% |
| Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S.IBSE: ANGEN | $31.63M | TL7.12 | -13.59% |
| GeneOne Life Science, Inc.KOSE: A011000 | $31.40M | ₩— | — |
| Medicure Inc.TSXV: MPH | $31.36M | CA$4.25 | +42.62% |
| Organoidsciences Ltd.KOSDAQ: A476040 | $31.32M | ₩6,340.00 | -7.45% |
Figures last refreshed Oct 18, 2026.